These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31563927)

  • 1. Poor outcomes in methamphetamine-associated cardiomyopathy-a growing health issue in New Zealand.
    Wang TKM; Kueh SA; Sutton T; Gabriel R; Lund M; Looi JL
    N Z Med J; 2019 Sep; 132(1502):55-66. PubMed ID: 31563927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand.
    Kueh SA; Gabriel RS; Lund M; Sutton T; Bradley J; Kerr AJ; Looi JL
    Heart Lung Circ; 2016 Nov; 25(11):1087-1093. PubMed ID: 27185546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Clinical Characteristics and Outcomes of Patients With Reversible Versus Persistent Methamphetamine-Associated Cardiomyopathy.
    Zhao SX; Seng S; Deluna A; Yu EC; Crawford MH
    Am J Cardiol; 2020 Jan; 125(1):127-134. PubMed ID: 31699360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis.
    Høfsten DE; Løgstrup BB; Møller JE; Pellikka PA; Egstrup K
    JACC Cardiovasc Imaging; 2009 May; 2(5):592-9. PubMed ID: 19442946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Methamphetamine-associated Cardiomyopathy and the Impact of Methamphetamine Use on Cardiac Dysfunction.
    Reddy PK; Chau E; Patel SV; Yang K; Ng TM; Elkayam U
    Am J Cardiol; 2021 Sep; 154():86-91. PubMed ID: 34233837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine-associated cardiomyopathy.
    Won S; Hong RA; Shohet RV; Seto TB; Parikh NI
    Clin Cardiol; 2013 Dec; 36(12):737-42. PubMed ID: 24037954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.
    Osekowski M; Trytell A; La Gerche A; Prior D; MacIsaac A; Paratz ED
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):385-393. PubMed ID: 35157254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
    Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
    Sutter ME; Gaedigk A; Albertson TE; Southard J; Owen KP; Mills LD; Diercks DB
    Clin Toxicol (Phila); 2013 Aug; 51(7):540-4. PubMed ID: 23855716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.
    Michtalik HJ; Yeh HC; Campbell CY; Haq N; Park H; Clarke W; Brotman DJ
    Am J Cardiol; 2011 Apr; 107(8):1191-5. PubMed ID: 21296322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes.
    Blauwet LA; Delgado-Montero A; Ryo K; Marek JJ; Alharethi R; Mather PJ; Modi K; Sheppard R; Thohan V; Pisarcik J; McNamara DM; Gorcsan J;
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27166247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Right Ventricular Dysfunction Severity Identifies Severe Peripartum Cardiomyopathy Phenotype With Worse Early and Overall Outcomes: A 24-Year Cohort Study.
    Peters A; Caroline M; Zhao H; Baldwin MR; Forfia PR; Tsai EJ
    J Am Heart Assoc; 2018 Apr; 7(9):. PubMed ID: 29686029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations.
    Mene-Afejuku TO; Dumancas C; Akinlonu A; Ola O; Cativo EH; Veranyan S; Lopez PD; Kim KS; Pekler G; Mushiyev S; Visco F
    Cardiovasc Hematol Agents Med Chem; 2019; 17(2):94-103. PubMed ID: 31875779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.